ixabepilone

Your doctor or pharmacist can provide more information about ixabepilone.

This list is not complete and other drugs may interact with ixabepilone.

Do not use ixabepilone if you are pregnant.

About 1 hour before you receive ixabepilone, you may be given other medications to help prevent certain side effects.

Avoid drinking alcohol during your treatment with ixabepilone.

To make sure you can safely receive ixabepilone, tell your doctor if you have any of these other conditions:

It is not known whether ixabepilone passes into breast milk or if it could harm a nursing baby.

You should not breast-feed while receiving ixabepilone.

Call your doctor for instructions if you miss an appointment for your ixabepilone injection.

Many drugs can interact with ixabepilone.

You may not be able to receive ixabepilone if you have severe liver disease, or severely low platelets or white blood cell counts.

Ixempra (ixabepilone)

Before you receive ixabepilone, tell your doctor if you have liver disease, heart disease, nerve problems, diabetes, bone marrow suppression, or a weak immune system.

Results of a phase III trial with ixabepilone in combination with capecitabine in metastatic breast cancer have been announced.

One such analog, known as Ixabepilone is a U.S. Food and Drug Administration approved chemotherapy agent for the treatment of metastatic breast cancer.

On October 16, 2007, the U.S. Food and Drug Administration approved ixabepilone for the treatment of aggressive metastatic or locally advanced breast cancer no longer responding to currently available chemotherapies.

The U.S. Food and Drug Administration has approved Ixempra (ixabepilone), a new anti-cancer treatment, for use in patients with metastatic or locally advanced breast cancer who have not responded to certain other cancer drugs.

Chemotherapy drugs associated with CIPN include thalidomide, the epothilones such as ixabepilone, the vinca alkaloids vincristine and vinblastine, the taxanes paclitaxel and docetaxel, the proteasome inhibitors such as bortezomib, and the platinum-based drugs cisplatin, oxaliplatin and carboplatin.